Efficacy of Arjuna ghana vati and Sarpagandha ghana vati in Hypertensio
- Conditions
- Health Condition 1: I10- Essential (primary) hypertension
- Registration Number
- CTRI/2022/07/043858
- Lead Sponsor
- Chaudhary Brahm Prakash Ayurved Charak Sansthan
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1.Patients with Stage 1 Hypertension according to JNC 8th Criteria
2.Patients presenting with symptoms of hypertension and comes under pre hypertension
3.Patients freshly diagnosed with hypertension
4.Patients who have been already diagnosed with hypertension and are not under regular medications for minimum of two months and comes under stage 1 hypertension
5.Patients with isolated systolic hypertension and
Essential hypertension
1.Patients below 18 years of age and above 60 years of age
2.Patient not willing for trial
3.Patients having systolic blood pressure greater than 160 mm hg and diastolic blood pressure greater than 100 mm hg
4.Complicated hypertensive cases like Nephropathy and left ventricular hypertrophy, Heart block congestive heart failure, coronary artery disease and retinopathy
5.Patients suffering with Diabetes mellitus
6.Patients with isolated diastolic hypertension,
Accelerated and malignant hypertension
7.Patient taking steroids, oral contraceptive pills. estrogen replacement therapy or NSAID group of drugs
8.Patient with severe other illness hepatic or renal failure
9.Secondary hypertension
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Improvement in the Systolic blood pressure, Diastolic blood pressure, Mean arterial PressureTimepoint: 0th,1st, 15th, 30th and 45th day of trial
- Secondary Outcome Measures
Name Time Method Improvement in the Lipid profiles (Total cholesterol, Triglycerides, High Density Lipoproteins, Low density Lipoproteins), two weeks sleep diary - intermittent awakenings in sleep, sleep duration, day time drowsiness, Subjective improvement in symptomsTimepoint: 0th day and 30th day of trial